Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Pinar Ataca Atilla"'
Autor:
Pinar Ataca Atilla, Erden Atilla
Publikováno v:
Translational Oncology, Vol 22, Iss , Pp 101459- (2022)
Chimeric antigen receptor T (CAR T) cell therapy is a new treatment paradigm that has revolutionized the treatment of CD19-positive B cell malignancies and BCMA-positive plasma cell malignancies. The response rates are highly impressive in comparison
Externí odkaz:
https://doaj.org/article/389bab64bf8146b7a55ea8097fcaea09
Autor:
Pinar Ataca Atilla, Mary K McKenna, Haruko Tashiro, Madhuwanti Srinivasan, Feiyan Mo, Brian Wesley Simons, Alexandra McLean Stevens, Michele S Redell, Helen E Heslop, Erden Atilla
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background C-type lectin-like molecule 1 (CLL-1) is highly expressed in acute myeloid leukemia (AML) but is absent in primitive hematopoietic progenitors, making it an attractive target for a chimeric antigen receptor (CAR) T-cell therapy. Here, we o
Externí odkaz:
https://doaj.org/article/7a32e4bf724e46cfb4155f71a646cc64
Publikováno v:
Biomedicines, Vol 9, Iss 9, p 1201 (2021)
NK (Natural Killer) cell-mediated adoptive immunotherapy has gained attention in hematology due to the progressing knowledge of NK cell receptor structure, biology and function. Today, challenges related to NK cell expansion and persistence in vivo a
Externí odkaz:
https://doaj.org/article/3c65b170da774a5eb828264c06846286
Autor:
Pinar Ataca Atilla, Mary K. McKenna, Norihiro Watanabe, Maksim Mamonkin, Malcolm K. Brenner, Erden Atilla
Publikováno v:
Cytotherapy
Efforts to safely and effectively treat acute myeloid leukemia (AML) by targeting a single leukemia-associated antigen with chimeric antigen receptor (CAR) T cells have met with limited success, due in part to heterogeneous expression of myeloid anti
Autor:
Pinar Ataca Atilla, Erden Atilla
Publikováno v:
Current Research in Translational Medicine. 71:103390
Publikováno v:
Biomedicines
Biomedicines, Vol 9, Iss 1201, p 1201 (2021)
Biomedicines, Vol 9, Iss 1201, p 1201 (2021)
NK (Natural Killer) cell-mediated adoptive immunotherapy has gained attention in hematology due to the progressing knowledge of NK cell receptor structure, biology and function. Today, challenges related to NK cell expansion and persistence in vivo a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3eff664cb29525ab71c7f01075bdf00e
https://hdl.handle.net/20.500.12445/2014
https://hdl.handle.net/20.500.12445/2014
Autor:
Osman Ilhan, Gunhan Gurman, Muhit Ozcan, Pinar Ataca Atilla, Meral Beksac, Ekin Kircali, Erden Atilla, Hamdi Akan, Pervin Topcuoglu, Klara Dalva, Hatice Ilgın Ruhi, Sinem Civriz Bozdag, Selami Kocak Toprak, Onder Arslan, Isinsu Kuzu
Publikováno v:
LLM Dergi. 4:45-49
Autor:
Erden Atilla, Meltem Kurt Yuksel, Pinar Ataca Atilla, Sinem Civriz Bozdag, Osman Ilhan, Selami Kocak Toprak, Meral Beksac, Muhit Ozcan, Pervin Topcuoglu, Gunhan Gurman, Onder Arslan
Publikováno v:
Ankara Üniversitesi Tıp Fakültesi Mecmuas, Vol 73, Iss 2, Pp 113-117 (2020)
Objectives:Myelodysplastic syndrome (MDS) is a clonal disease that progresses with cytopenias and has leukemia transformation. Allogeneic Stem Cell Transplantation (ASCT) is a curative treatment in MDS patients. However, to which patient group the AS
Autor:
Tyler Smith, Royce Ma, Erden Atilla, David H. Quach, Norihiro Watanabe, Pinar Ataca Atilla, Diogo Gomes-Silva, Helen E. Heslop, Mary K. McKenna, Maksim Mamonkin, Malcolm K. Brenner, Madhuwanti Srinivasan, M. John Hicks, Feiyan Mo
Publikováno v:
Nature biotechnology
Engineered T cells are effective therapies against a range of malignancies, but current approaches rely on autologous T cells, which are difficult and expensive to manufacture. Efforts to develop potent allogeneic T cells that are not rejected by the
Autor:
Bengü Nisa Akay, Pinar Ataca Atilla, Meltem Kurt Yuksel, Pervin Topçuoğlu, Hatice Sanli, Muhit Ozcan, Selami Kocak Toprak, Guldane Cengiz Seval, Erden Atilla, Sinem Civriz Bozdağ, Onder Arslan, Gunhan Gurman
Publikováno v:
LLM Dergi. 4:23-27